Alcidion Group Limited (ASX: ALC) - Share Price
Current share price for ALC : $0.100 0.002 (2.44%)+
Alcidion Group Limited (ALC), an ASX-listed company, is a Company that is engaged in the development and licensing of its healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its partners and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in Australia, New Zealand and the United Kingdom.
ALC General Information +
| ASX Code | ALC |
| Website | http://www.alcidion.com |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 134 |
| ALC Share Price | $0.100 |
| Day High | $0.103 |
| Day Low | $0.100 |
| Last Close | $0.103 |
| ALC Share Price Movement | $0.00 ( 2.44% ) |
Prices as at 16:40, 11 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Alcidion Group Limited (ALC) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Alcidion Group Limited (ALC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Alcidion Group Limited (ALC) price-sensitive announcements
ALC - ALC signs 7-year contract with UHSussex for EPR platform
Alcidion Group Limited has entered into a 7-year agreement with University Hospitals Susse
Alcidion Group Limited (ALC)
25 May 2026 | 8:21 AM
25 May 2026 | 8:21 AM
ALC - Acquisition of the Kyra flow products from Telstra Health
Alcidion Group Limited has signed an Asset Sale Agreement to acquire the Kyra flow product
Alcidion Group Limited (ALC)
18 May 2026 | 8:57 AM
18 May 2026 | 8:57 AM
ALC - Q3 FY26 Quarterly Activities Report and Appendix 4C
Alcidion Group Limited reported a strong Q3 FY26 with revenue expected to exceed $50.0M an
Alcidion Group Limited (ALC)
29 Apr 2026 | 8:22 AM
29 Apr 2026 | 8:22 AM
ALC - H1 FY26 Results Presentation
The H1 FY26 Results Presentation for Alcidion Group Limited highlights the company's finan
Alcidion Group Limited (ALC)
26 Feb 2026 | 7:54 AM
26 Feb 2026 | 7:54 AM
Alcidion Group Limited (ALC) Recent ASX Announcements
ALC Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | $0.20 | 50.00% | 66.70 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | $0.10 | -16.70% | 100.00 | 0.00 | 0.00% | 0.0% |
| 2025A | $1.65 | $0.10 | -118.80% | 59.40 | 0.00 | 0.00% | 0.0% |
ALC Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| 4DMedical Limited (4DX) | $2,172M | 0.3304 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Alcidion Group Limited (ALC) | $138M | -1.1875 | -0.1667 | 0.5000 | 85.4167 | 102.5000 | 68.3333 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $16,880M | 0.3919 | 0.2545 | 0.2962 | 146.7575 | 116.9852 | 90.2530 | 0.34% | 0.44% | 0.57% |
ALC Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.56 | 99.00 | 1.53 | 8.38 |
| Market | 0.36 | 12.80 | 1.14 | 0.70 |
| Sector | 0.66 | 20.90 | 1.55 | 3.20 |
ALC Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Katrina (Kate) Elizabeth Doyle (Quirke) | Chief Executive Officer, Executive Director, Managing Director | 3 Jul 2018 |
| Mr William (Bill) Smart | Non-Executive Director | 1 Oct 2024 |
| Mr Daniel Sharp | Non-Executive Director | 1 Sep 2021 |
| Professor Andrew Way | Non-Executive Director | 15 Apr 2025 |
| Ms Rebecca Jayne Wilson | Non-Executive Director, Non-Executive Chairman | 31 Jul 2017 |
Alcidion Group Limited (ALC) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 4 Mar 2025 | DOYLE (QUIRKE), Katrina (Kate) | Sell | Direct Shares | 5,000,000 | $0.085 | $425,000.000 |
| 26 Apr 2024 | SHARP, Daniel | Buy | Direct Shares | 250,000 | $0.052 | $13,070.000 |
| 23 Apr 2024 | DOYLE (QUIRKE), Katrina (Kate) | Buy | Indirect Shares | 1,000,000 | $0.047 | $46,671.000 |
See all changes in directors' interest & trades for Alcidion Group Limited (ALC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ALC Management
| Name | Position |
|---|---|
| Matthew Gepp | Chief Financial Officer |
| Michael Sapountzis | Company Secretary |
ALC Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Alcidion Group Limited (ALC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 153,116,042 (11.40%) | AustralianSuper Pty Limited |
| 116,416,160 (8.67%) | Malcolm Pradhan |
| 68,664,657 (5.11%) | Raymond Howard Blight |
ALC Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 27 August 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
